6 recruiting, 1 not yet recruiting, 1 unknown. 6 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 5, Not yet recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Unknown 1 |
Follow Multiple Myeloma, Newly Diagnosed: new trials by email Literature Review of Multiple Myeloma, Newly Diagnosed trials Research Report on Multiple Myeloma, Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Newly Diagnosed | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2025-08-10 | 2025-08-06 |
| MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Newly Diagnosed | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2025-08-10 | 2025-08-06 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex) - Multiple Myeloma, Newly Diagnosed | Phase 3 | Recruiting | Intergroupe Francophone du Myelome | 824 | 2025-07-09 | 2026-09-30 |
| Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT autologous stem cell transplantation, CAR-T - Multiple Myeloma, Newly Diagnosed | Phase 2 | Not yet recruiting | Xuzhou Medical University | 60 | 2025-05-01 | 2025-05-09 |
| Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients Low-dose teclistamab - Multiple Myeloma, Newly Diagnosed | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 10 | 2025-03-03 | 2025-03-20 |
| KPD Consolidation After ASCT in NDMM Patients KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation - Multiple Myeloma, Newly Diagnosed | Phase 2 / Phase 3 | Recruiting | Peking University People's Hospital | 202 | 2025-03-01 | 2025-03-17 |
| Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma dynamic MRI and bone marrow sampling - Multiple Myeloma, Newly Diagnosed | Not applicable | Unknown | National Taiwan University Hospital | 40 | 2005-07-01 | 2005-11-24 |
Multiple Myeloma (8) · Bites and Stings (2)
Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Plasma Cell (8) · Paraproteinemias (8) · Vascular Diseases (8) · Chemically-Induced Disorders (2)
Dexamethasone (2) · Lenalidomide (2) · daratumumab (2) · Bortezomib (1) · carfilzomib (1) · pomalidomide (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Intergroupe Francophone du Myelome (1) · National Taiwan University Hospital (1) · Peking University People's Hospital (1) · SCRI Development Innovations, LLC (1) · Xuzhou Medical University (1)
China (4) · Belgium (1) · France (1) · Mexico (1) · Taiwan (1) · United States (1)
Henning Schade, MD (1) · Jin Lu, M.D. (1) · Kailin Xu (1) · Shang-Yi Huang, M.D. (1)